Searchable abstracts of presentations at key conferences in endocrinology

ea0013p179 | Diabetes, metabolism and cardiovascular | SFEBES2007

A characterisation of novel lipase expression and glucocorticoid regulation of lipolysis in human adipose tissue

Gathercole Laura , Bujalska Iwona , Morgan Stuart , Stewart Paul , Tomlinson Jeremy

Glucocorticoids (GC) have potent actions upon human adipose tissue, promoting adipocyte differentiation, inhibiting preadipocyte proliferation and inducing lipolysis to generate free fatty acids (FFA) and glycerol through a putative action upon hormone sensitive lipase (HSL). FFA have been strongly implicated in the pathogenesis of insulin resistance, yet the molecular mechanisms that cause GC induced lipolysis are not clear. Recently, several novel lipases have been identifie...

ea0013p181 | Diabetes, metabolism and cardiovascular | SFEBES2007

TRB3: A mechanism for glucocorticoid induced insulin sensitisation in human adipocytes

Gathercole Laura , Bujalska Iwona , Stewart Paul , Tomlinson Jeremy

Glucocorticoid (GC) excess is characterized by central obesity, insulin resistance and in some cases, type 2 diabetes mellitus. Whilst it is accepted that GCs cause insulin resistance, both insulin and GCs act synergistically to promote adipocyte differentiation. We have previously shown that GCs cause tissue specific changes in insulin sensitivity, enhancing insulin signalling in human adipose tissue in contrast to muscle.TRB3, a mammalian homolog of <i...

ea0056gp115 | Diabetes Translational | ECE2018

Male AKR1D1 (5β-reductase) knockout mice have altered pancreatic islet morphology and hormone secretion

Harris Shelley , Gathercole Laura , Ramracheya Reshma , Forhead Alison , Tomlinson Jeremy

The enzyme 5β-reductase (AKR1D1) catalyses an essential step in bile acid (BA) synthesis, but in addition, controls intra-cellular steroid hormone availability by inactivation. Steroid hormones and BA are regulators of global lipid and carbohydrate metabolism. As disturbances in steroid hormone and BA metabolism have potent effects on metabolic health, we hypothesize that AKR1D1 may play a role in metabolic homeostasis. The role of AKR1D1 in regulating glucose homeostasis...

ea0081yi8 | Young Investigator Awards | ECE2022

AKR1D1 knockdown identifies 7α-hydroxy-3-oxo-4-cholestenoic acid (7-HOCA) as a driver of metabolic dysfunction and hepatocellular cancer risk in patients with non-alcoholic fatty liver disease (NAFLD)

Nikolaou Nikolaos , Arvaniti Anastasia , Sanna Fabio , da Conceicao Ragazzon , Dempster Niall , Gathercole Laura , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from simple intrahepatic lipid accumulation to fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 5β-reductase (AKR1D1) is a liver enzyme that catalyses a fundamental step in bile acid (BA) synthesis. Both BAs and BA intermediates are established as potent regulators of metabolic and proliferative phenotype. We have hypothesised that AKR1D1 plays a crucial role in NAFLD and HCC. Human liver b...

ea0081rc10.3 | Rapid Communications 10: Diabetes, Obesity, Metabolism and Nutrition 3 | ECE2022

Primary bile acids differentially regulate differentiation of human abdominal and gluteal pre-adipocytes

Sabaratnam Rugivan , da Conceicao Ismael , Loh Nellie , Christodoulides Constantinos , Karpe Fredrik , Tomlinson Jeremy , Nikolaou Nikolaos

Bile acids (BAs) are synthesised from cholesterol in the liver and promote lipid digestion. An emerging body of evidence, however, suggests that BAs are also key signaling molecules with potent metabolic and endocrine functions, exerting their effects through activation of BA receptors, including the farnesoid-X- (FXR) and the G-protein-coupled- (TGR5) receptors. Disturbed BA synthesis has been associated with type 2 diabetes mellitus and insulin resistance, and recent studies...

ea0081p370 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Differential localisation of the A-ring reductases in human hepatocytes: implications for substrate preference and utilisation

Potter Tom , da Conceicao Ismael , Nikolaou Nikolaos , Loh Nellie , Tomlinson Jeremy , Gathercole Laura

The 5-reductases are steroid metabolising enzymes that saturate the C4=C5 bond of the steroid A-ring, and their substrates include androgens, glucocorticoids, and bile acids. 5β-reductases (SRD5A1 & SRD5A2) convert testosterone to the more potent androgen 5β-dihydrotestosterone, and carry out the first step in glucocorticoid clearance, generating 5β-dihydrocortisol from cortisol. 5β-reductase (AKR1D1) is also able to carry out the first step of glucocor...

ea0050oc1.2 | Early Career Oral Communications | SFEBES2017

Co-administration of 5α-reductase inhibitors worsens the adverse metabolic effects of prescribed glucocorticoids

Marjot Tom , Othonos Nantia , Woods Conor , Hazlehurst Jonathan , Moolla Ahmad , Hodson Leanne , Tomlinson Jeremy

Glucocorticoids (GC) are commonly prescribed and their use is associated with adverse metabolic side effects. 5a-reductase (5aR) inhibitors are also frequently prescribed mainly for their ability to inhibit the conversion of testosterone to dihydrotestosterone. However, they also have a role to inactivate and clear GCs. We hypothesised that 5aR inhibitors have the potential to exacerbate the adverse metabolic effects of GCs. We conducted a prospective, randomised, study in 19 ...

ea0050p206 | Diabetes and Cardiovascular | SFEBES2017

The impact of a dedicated metabolic hepatology clinic for the treatment of non-alcoholic fatty liver disease

Motohashi Kenzo , Moolla Ahmad , Marjot Tom , Ainsworth Mark , Tomlinson Jeremy , Cobbold Jeremy

Introduction: Non-Alcoholic Fatty Liver Disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is tightly associated with insulin resistance and type 2 diabetes (T2DM), both risk factors for disease progression, liver failure and cardiovascular complications. A multidisciplinary approach involving hepatologists and diabetologists working alongside allied health professionals is thus advocated for the management of NAFLD. Interv...

ea0050p319 | Obesity and Metabolism | SFEBES2017

The adverse metabolic phenotype associated with obstructive sleep apnoea is not driven by activation of the hypothalamo-pituitary-adrenal axis

Hazlehurst Jonathan M , Charlton Catriona , Mantripp Diana , Hodson Leanne , Tomlinson Jeremy W

Glucocorticoid (GC) excess drives obesity, insulin resistance and type 2 diabetes. Obstructive sleep apnoea (OSA) is a prevalent condition associated with both activation of the hypothalamic-pituitary-adrenal (HPA) axis and an adverse metabolic phenotype. However, a causal link between these two features has not been established. We designed a novel human model of intermittent hypoxia (IH) aimed at replicating the systemic insulin resistance associ...